Tenecteplase outperforms standard stroke treatment
Tenecteplase, a clot buster used off-label for treating ischemic stroke, outperforms alteplase, the standard treatment, in health outcomes and cost, researchers reported on September 23, 2022 in Stroke. Tenecteplase is administered in a single five- to 10-second intravenous injection. Alteplase is injected over a 60-minute period. “When it comes to treating patients with a stroke, every second matters,” said lead […]
Recent Comments